{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T10:54:56Z","timestamp":1762685696481,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cllc.2021.07.006","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T05:59:37Z","timestamp":1626760777000},"page":"e140-e147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Shigeki","family":"Umemura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joeffrey J","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Kallakury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Avantaggiati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2021.07.006_bib0001","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2021.07.006_bib0002","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","article-title":"Chemotherapy and targeted agents for thymic malignancies","volume":"12","author":"Girard","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cllc.2021.07.006_bib0003","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2021.07.006_bib0004","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.07.006_bib0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2021.07.006_bib0006","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e318286cf88","article-title":"Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches","volume":"8","author":"Spigel","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.07.006_bib0007","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cllc.2021.07.006_bib0008","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2021.07.006_bib0009","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.07.006_bib0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tips.2015.03.006","article-title":"Arginase: an old enzyme with new tricks","volume":"36","author":"Caldwell","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cllc.2021.07.006_bib0011","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodr\u00edguez","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cllc.2021.07.006_bib0012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2021.07.006_bib0013","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2021.07.006_bib0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2021.07.006_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.csbj.2015.03.008","article-title":"A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy","volume":"13","author":"Leone","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.cllc.2021.07.006_bib0016","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/1873-3468.12784","article-title":"Immunosuppressive enzymes in the tumor microenvironment","volume":"591","author":"Molinier-Frenkel","year":"2017","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cllc.2021.07.006_bib0017","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/cells9030561","article-title":"Myeloid-derived suppressor cells as a therapeutic target for cancer","volume":"9","author":"Law","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.cllc.2021.07.006_bib0018","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.3390\/ijms21145089","article-title":"The adenosine system at the crossroads of intestinal inflammation and neoplasia","volume":"21","author":"D'Antongiovanni","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cllc.2021.07.006_bib0019","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1158\/1078-0432.CCR-12-3260","article-title":"Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors","volume":"19","author":"Petrini","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2021.07.006_bib0020","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2019.01.019","article-title":"Surgical resection of SCLC: prognostic factors and the tumor microenvironment","volume":"14","author":"Zhao","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"7 Suppl 3","key":"10.1016\/j.cllc.2021.07.006_bib0021","doi-asserted-by":"crossref","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.07.006_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14740\/gr1156","article-title":"Well differentiated arginase-1 negative hepatocellular carcinoma","volume":"12","author":"Obiorah","year":"2019","journal-title":"Gastroenterology Res"},{"key":"10.1016\/j.cllc.2021.07.006_bib0023","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid cell-derived arginase in cancer immune response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.cllc.2021.07.006_bib0024","series-title":"44th ESMO Congress","article-title":"Phase I study of the arginase inhibitor INCB (1158) 001158: alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced\/metastatic (adv\/met) solid tumours","author":"Naing","year":"2019"},{"key":"10.1016\/j.cllc.2021.07.006_bib0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2326-6066.CIR-14-0018","article-title":"Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity","volume":"3","author":"Bastid","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.cllc.2021.07.006_bib0026","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","article-title":"Targeting CD39 in cancer","volume":"20","author":"Moesta","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cllc.2021.07.006_bib0027","doi-asserted-by":"crossref","first-page":"e4989","DOI":"10.1097\/MD.0000000000004989","article-title":"Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection","volume":"95","author":"Cai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cllc.2021.07.006_bib0028","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3892\/ol.2016.5189","article-title":"High expression of CD39 in gastric cancer reduces patient outcome following radical resection","volume":"12","author":"Cai","year":"2016","journal-title":"Oncol Lett"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042100187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042100187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:12:17Z","timestamp":1761505937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042100187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S152573042100187X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2021.07.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}